UNCY — Unicycive Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSmall Cap
- $133.89m
- $91.20m
Annual cashflow statement for Unicycive Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.26 | -10 | -18.1 | -30.5 | -36.7 |
| Depreciation | |||||
| Non-Cash Items | 0.971 | 4.35 | 1.22 | 12.3 | 8.56 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.166 | -0.105 | 1.18 | -0.093 | -0.426 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.46 | -5.77 | -15.7 | -18.3 | -28.6 |
| Capital Expenditures | — | -0.029 | -0.002 | -0.012 | -0.072 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | — | -0.029 | -0.002 | -0.012 | -0.072 |
| Financing Cash Flow Items | -0.117 | 0 | -0.482 | -0.496 | -0.687 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.44 | 22.4 | -0.471 | 27.5 | 45.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.015 | 16.6 | -16.1 | 9.25 | 16.4 |